Corvus Pharmaceuticals (CRVS)
Develops immune-disease and cancer therapies centered on soquelitinib.
Something off on this page? Send us feedback.
Develops clinical-stage therapies for immune diseases and cancer, led by the oral ITK inhibitor soquelitinib. The pipeline also includes ciforadenant and mupadolimab, with Greater China rights held through Angel Pharmaceuticals and no product-sales revenue.
Develops clinical-stage therapies for immune diseases and cancer around immune-modulation biology. Soquelitinib is the lead program, an oral investigational ITK inhibitor being advanced in relapsed T-cell lymphomas and inflammatory diseases such as atopic dermatitis.
Ciforadenant targets adenosine A2A receptor signaling in the tumor microenvironment, while mupadolimab is an anti-CD73 antibody tied to adenosine production and B-cell binding. The portfolio remains investigational, with no approved products or product-sales revenue.
Based in South San Francisco, the company owns worldwide rights outside Greater China, where Angel Pharmaceuticals develops and commercializes the same core candidates. Its business depends on clinical-trial execution, regulatory approval, intellectual-property protection, and continued financing before commercial revenue can begin.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Apr 17, 2026 | Goldman Sachs | Target | Target: — | Target: $40 |
| Jan 29, 2026 | Mizuho Securities | Target | Target: $20 | Target: $30 |
| Jan 22, 2026 | Jefferies | Reiterate | Rating: —Target: $13 | Target: $42 |
| Jan 21, 2026 | Oppenheimer | Reiterate | Rating: —Target: $7 | Target: $32 |
| Jan 20, 2026 | Barclays | Target | Target: $16 | Target: $28 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $215.2M · Total debt $728.0K · Total assets $239.3M · Shareholders' equity $225.3M
- Revenue
- $0
- Operating income
- −$19.3M
- Net income
- −$18.0M
No dividends on record.
| Institutions | ≈ 83.11% | 69.91M shares | |
|---|---|---|---|
| 188 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 7.91% | 6.66M shares | |
| 5 holders · as of Jun 15, 2026 | |||
| Other | ≈ 8.98% | 7.55M shares | |
| remainder | |||
84.12M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Orbimed Advisors LLCInstitution | 8.52% | 7.17M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 8.49% | 7.14M | as of Jun 30, 2026 |
Sirenia Capital Management LPInstitution | 8.12% | 6.83M | filed May 15, 2026 |
Richard A. Md Miller1Insiderdirector, officer: President and CEO | 7.24% | 6.09M | filed May 20, 2026 |
State Street CorpInstitution | 5.32% | 4.47M | as of Jun 30, 2026 |
- Richard A. Md Miller's transaction reports restate only vehicles that traded; the 2026 ownership statement (6.09M) plus the 6.9K net shares acquired since is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 11, 2026 | David Scott Moore | director | +21,700 | $11.53 |
| May 18, 2026 | Richard A. Md Miller | director, officer: President and CEO | +6,932 | $12.04 |
- Aclaris Therapeutics
Direct oral ITK/JAK3 peer in atopic dermatitis
- Innate Pharma (ADR)
Lacutamab targets CTCL and PTCL through KIR3DL2
- Regeneron
Dupixent sets the AD and asthma efficacy benchmark
- Citius Oncology
Commercial CTCL immunotherapy in the U.S.
- AbbVie
Oral JAK benchmark for moderate-to-severe AD
- Arcus Biosciences
CD73 and adenosine-pathway oncology peer
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals | $12.60 | −6.28% | $1.13B | — | — | — | — |
| Aclaris Therapeutics | $5.42 | −5.19% | $798.9M | — | — | 97.2 | −8.3% |
| Innate Pharma (ADR) | $1.79 | −0.56% | $169.0M | — | — | 136.6 | +12.9% |
| Regeneron | $796.68 | −0.90% | $82.82B | 19.9 | 13.2 | 5.3 | +16.7% |
| Citius Oncology | $1.02 | −4.67% | $99.5M | — | — | 14.0 | — |
| AbbVie | $266.18 | +0.37% | $468.77B | 74.8 | 17.5 | 7.3 | +10.2% |
| Arcus Biosciences | $26.53 | −1.27% | $3.38B | — | — | 28.9 | −74.4% |
| Median | 47.3 | 15.3 | 21.4 | +10.2% |